Abstract 1677P
Background
Chemotherapy (CT) often triggers physical and emotional changes impacting patients' lives, including their sexuality. Addressing sexual health (SH) issues is crucial for comprehensive cancer care. The aim of our study was to identify SH and intimacy issues in the Tunisian context among men undergoing CT.
Methods
The study was a cross-sectional, anonymous questionnaire-based study, conducted between March and May 2024 including 80 male cancer patients undergoing CT. Urological cancer patients were excluded. SH was evaluated by the EORTC Quality of Life Questionnaire Sexual Health (QLQ SH-22), which includes assessments of sexual satisfaction, sexual pain, sexual activity, treatment and partner-related issues. A higher score represents a higher level of symptomatology.
Results
Median age was 59.5 years [32-73]. Sixty-six patients (83%) were married and 79% were sexually active before the diagnosis. Colon cancer was the most common primary cancer (44%), followed by lung (20%) and pancreas (14%). Tumors were non metastatic in 55% of cases. The importance of communication about SH between doctors and patients was highlighted by 69% of respondents especially in those under 50 years old (95%). However, 59% considered it insufficient during checkups. The most commonly reported reason, cited by over half of patients (53%), was a lack of initiative on the part of physicians. Fifty-four patients (68%) expressed the importance of maintaining sexual activity. Yet only 33 (41%) remained sexually active during CT. Decreased libido was reported by 49 (61%) patients. Fifty-eight (73%) patients perceived a negative impact of CT on their SH. Forty-seven patients (59%) expressed dissatisfaction with communication about SH with their partners. The median sexual satisfaction score was 36 [3-60], with no correlation observed with socioeconomic status (p=0.89), educational level (p=0.09) or site of cancer (p=0.12). It was significantly higher among unmarried patients (OR=5.42, p=0.027) and in those with metastatic disease (OR=3.26, p=0.012).
Conclusions
The diagnosis and treatment of cancer significantly affect SH. Thus, providing sexual counseling to patients, especially in Arab countries where cancer and sexuality remain taboo, is essential to effectively meet their needs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1636P - Health-related quality of life outcomes of androgen receptor pathway inhibitors versus taxanes versus standard of care in metastatic castration-resistant prostate cancer: Results from the ProBio trial
Presenter: Renée Bultijnck
Session: Poster session 11
1637P - Efficacy of talazoparib and enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel: Post hoc analysis from both cohorts in TALAPRO-2 study
Presenter: Neeraj Agarwal
Session: Poster session 11
1638P - Enzalutamide (enza) with or without leuprolide in patients (pts) with high-risk biochemically recurrent (hrBCR) prostate cancer (PC): EMBARK post hoc analysis by age
Presenter: Neal Shore
Session: Poster session 11
1639P - Self efficacy in people with prostate cancer in the UK: A large, digital survey
Presenter: Joe O'Sullivan
Session: Poster session 11
1640P - Development and validation of a machine learning-based risk model for metastatic disease in nmCRPC patients
Presenter: Ziyun Wang
Session: Poster session 11
1641P - Phase I/II trial of oral masofaniten (EPI-7386) in combination with enzalutamide (Enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects
Presenter: Christos Kyriakopoulos
Session: Poster session 11
1642P - Integrated prognostic score in metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel: A CABASTY posthoc analysis
Presenter: Charles Vauchier
Session: Poster session 11
1643P - Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC)
Presenter: Bicky Thapa
Session: Poster session 11
1644P - PSA trajectories and prediction of time to no-longer clinically benefitting in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
Presenter: Lana Broer
Session: Poster session 11
1645P - Tumour suppressor gene signature predicts early progression in metastatic hormone-sensitive metastatic prostate cancer (mHSPC) patients
Presenter: Marta Garcia De Herreros
Session: Poster session 11